目的：对比分析培美曲塞（pemetrexed，MTA）联合顺铂（cisplatin，DDP）与多西他赛（docetaxel，TXT）联合顺铂（DDP）应用于非小细胞肺癌（ non－small cell lung cancer ，NSCLC）的治疗效果。方法选取2013年5月1日～2015年5月1日在安顺市人民医院接受化疗的50例NSCLC患者，随机分为MTA和TXT组，每组25例，并分别采用MTA联合DDP方案和TXT联合DDP方案进行治疗，治疗1个疗程总共21 d。对2种治疗方案的效果以及不良反应进行对比。结果经过治疗后，MTA组、TXT组的可溶性细胞间黏附因子－1（soluble intercellular adhesion molecule 1，sICAM－1）和可溶性血管细胞粘附分子1（soluble vasccular cell adhesion molecule 1， sVCAM－1）水平明显降低（P＜0．05），2组治疗后sICAM－1和sVCAM－1水平无显著差异。治疗后MTA组的总有效率（20．00％）与TXT组（16．00％）比较，差异无统计学意义（χ2＝0．136，P＞0．05）。 MTA组发生恶心呕吐、贫血、血小板降低、中性粒细胞降低、脱发的不良反应率（40．00％）低于TXT组（72．00％）（χ2＝5．195，P＜0．05）。结论 MTA联合DDP方案治疗NSCLC的效果与TXT联合DDP方案比较无明显差异，但不良反应发生率低。%Objective To compare efficacy of pemetrexed (MTA) combined with cisplatin (DDP) and docetaxel (TXT) combined with DDP in treatment of non-small cell lung cancer (NSCLC).Methods 50 patients with NSCLC from May 1, 2013 to May 1, 2015 in the hospital were seleced and randomly divided into two groups:MTA group (n=25) were received MTA combined with DDP, and TXT group(n=25) were received TXT combined with DDP, for a course of twenty-one days.After treatment, the efficacy of two therapy as well as adverse reactions were compared.ResuIts After treatment, the soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vasccular cell adhesion molecule 1 (sVCAM-1) levels in MTA group were significantly lower than those before treatment (P0.05).The adverse reaction of nausea and vomiting, anemia, low platelet count, neutropenia and alopecia in MTA group was lower than that in TXT group (40.00%vs.72.00%,χ2 =5.195,P<0.05).ConcIusion The efficacy of MTA combined with DDP and TXT combined with DDP in treatment of NSCLC is similar, but the adverse reactions of fomer one is lower.
展开▼
